{"schema_version":"secwatch.filing_event.v1","accession":"0001731122-26-000221","form_type":"8-K","ticker":"LNAI","cik":"0001527728","company_name":"Lunai Bioworks Inc.","filed_at":"2026-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.334823+00:00","generated_at":"2026-05-16T03:00:23.377919+00:00","sec_items":["3.01","7.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Lunai Bioworks receives Nasdaq delisting notice; appeals hearing requested","bullets":["Notice received Feb 6, 2026: bid price closed below $1.00 for 30 consecutive business days through Feb 5, 2026.","Ineligible for 180-day compliance period due to 1-for-10 reverse stock split on Sep 30, 2025 (Nasdaq Rule 5810(c)(3)(A)(iv)).","Suspension and Form 25 filing scheduled for Feb 18, 2026 unless hearing request stays action.","Company timely requested hearing before Nasdaq Hearings Panel by Feb 13, 2026; outcome uncertain.","Delisting would deregister securities under Section 12(b) of Exchange Act."],"urls":{"canonical":"https://secwatch.observer/filing/0001731122-26-000221","json":"https://secwatch.observer/filing/0001731122-26-000221.json","markdown":"https://secwatch.observer/filing/0001731122-26-000221.md","text":"https://secwatch.observer/filing/0001731122-26-000221.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1527728/000173112226000221/0001731122-26-000221-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1527728/000173112226000221/e7323_8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T03:00:23.377919+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"82aebf21bee25232335edd5823cd539e3ce59786","claim":"Lunai Bioworks Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iv)).","evidence_excerpt":"February 6, 2026, Lunai Bioworks, Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that Nasdaq staff has determined to delist the Company’s securities from The Nasdaq Capital Market. The Notice states that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share, as the bid price of the Company’s securities closed below $1.00 per share for 30 consecutive business days from December 23, 2025 through February 5","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112226000221/0001731122-26-000221-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001213900-26-062935","ticker":"ATNM","company_name":"Actinium Pharmaceuticals, Inc.","filed_at":"2026-05-29T21:10:41+00:00","headline":"Actinium receives NYSE American non-compliance notice for low stockholders' equity; must submit plan by June 26","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 7.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-062935","json":"https://secwatch.observer/filing/0001213900-26-062935.json","markdown":"https://secwatch.observer/filing/0001213900-26-062935.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/0001213900-26-062935-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/ea0292691-8k_actinium.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"February 6, 2026, Lunai Bioworks, Inc. (the “Company”)\nreceived a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)\nnotifying the Company that Nasdaq staff has determined to delist the Company’s securities from The Nasdaq Capital Market. The Notice states that the Company is not in compliance with Nasdaq Listing\nRule 5550(a)(2), which requires a minimum bid price of $1.00 per share, as the bid price of the Company’s securities closed below\n$1.00 per share for 30 consecutive business days from December 23, 2025 through February 5","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112226000221/0001731122-26-000221-index.htm","comparable_excerpt":"May 27, 2026, Actinium Pharmaceuticals, Inc.\n(the “Company”) received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating\nthat the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company\nGuide (the “Company Guide”), which requires a listed company to maintain stockholders’ equity of $4.0 million or more\nif it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31,\n2026, the Company reported stockholders’ equity of approximately","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/0001213900-26-062935-index.htm"}},{"accession":"0001493152-26-025277","ticker":"VSTD","company_name":"Vestand Inc.","filed_at":"2026-05-26T21:18:59+00:00","headline":"Vestand receives Nasdaq delisting notice for late quarterly and annual filings","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 7.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-025277","json":"https://secwatch.observer/filing/0001493152-26-025277.json","markdown":"https://secwatch.observer/filing/0001493152-26-025277.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1898604/000149315226025277/0001493152-26-025277-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1898604/000149315226025277/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"February 6, 2026, Lunai Bioworks, Inc. (the “Company”)\nreceived a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)\nnotifying the Company that Nasdaq staff has determined to delist the Company’s securities from The Nasdaq Capital Market. The Notice states that the Company is not in compliance with Nasdaq Listing\nRule 5550(a)(2), which requires a minimum bid price of $1.00 per share, as the bid price of the Company’s securities closed below\n$1.00 per share for 30 consecutive business days from December 23, 2025 through February 5","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112226000221/0001731122-26-000221-index.htm","comparable_excerpt":"May 19, 2026, the Company received a Staff Delisting Determination letter (the “Staff Determination”) from Nasdaq notifying\nit that Nasdaq has initiated a process which could result in the delisting of the Company’s secu","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1898604/000149315226025277/0001493152-26-025277-index.htm"}},{"accession":"0001836875-26-000036","ticker":"NVVE","company_name":"Nuvve Holding Corp.","filed_at":"2026-05-22T22:35:13+00:00","headline":"Nuvve receives Nasdaq delisting notice for late Q1 10-Q filing; already under $1.00 bid price review","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 7.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001836875-26-000036","json":"https://secwatch.observer/filing/0001836875-26-000036.json","markdown":"https://secwatch.observer/filing/0001836875-26-000036.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1836875/000183687526000036/0001836875-26-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1836875/000183687526000036/nvve-20260522.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"February 6, 2026, Lunai Bioworks, Inc. (the “Company”)\nreceived a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)\nnotifying the Company that Nasdaq staff has determined to delist the Company’s securities from The Nasdaq Capital Market. The Notice states that the Company is not in compliance with Nasdaq Listing\nRule 5550(a)(2), which requires a minimum bid price of $1.00 per share, as the bid price of the Company’s securities closed below\n$1.00 per share for 30 consecutive business days from December 23, 2025 through February 5","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112226000221/0001731122-26-000221-index.htm","comparable_excerpt":"May 22, 2026, Nuvve Holding Corp. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, since the Company","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1836875/000183687526000036/0001836875-26-000036-index.htm"}},{"accession":"0001213900-26-054565","ticker":"AGAE","company_name":"Allied Gaming & Entertainment Inc.","filed_at":"2026-05-11T21:09:36+00:00","headline":"AGAE receives Nasdaq delisting notice over bid price <$1.00 and late 10-K; will appeal","event_type":"regulatory","sec_items":["3.01","5.03","7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 7.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-054565","json":"https://secwatch.observer/filing/0001213900-26-054565.json","markdown":"https://secwatch.observer/filing/0001213900-26-054565.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708341/000121390026054565/0001213900-26-054565-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708341/000121390026054565/ea0290063-8k_allied.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"February 6, 2026, Lunai Bioworks, Inc. (the “Company”)\nreceived a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)\nnotifying the Company that Nasdaq staff has determined to delist the Company’s securities from The Nasdaq Capital Market. The Notice states that the Company is not in compliance with Nasdaq Listing\nRule 5550(a)(2), which requires a minimum bid price of $1.00 per share, as the bid price of the Company’s securities closed below\n$1.00 per share for 30 consecutive business days from December 23, 2025 through February 5","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112226000221/0001731122-26-000221-index.htm","comparable_excerpt":"termination\nbefore an independent Hearings Panel (the “Panel”) by May 13, 2026. On November 4, 2025, Staff notified the Company\nthat the bid price of the Common Stock had closed at less than $1.00 per share over 30 consecutive business days, and, as a result, did\nnot comply with Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”). The Staff Determination was issued pursuant\nto Nasdaq Listing Rule 5810(c)(3)(A) on the grounds that the Company has not regained compliance with the Minimum Bid Price Rule during\na 180-day compliance period and is not eligible for a second 180-day complian","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1708341/000121390026054565/0001213900-26-054565-index.htm"}},{"accession":"0001731122-26-000668","ticker":"SBEV","company_name":"SPLASH BEVERAGE GROUP, INC.","filed_at":"2026-05-05T23:59:59+00:00","headline":"Splash Beverage receives NYSE delisting notice; shareholders' equity negative $15.3M","event_type":"regulatory","sec_items":["1.01","1.02","3.01","3.02","5.03","7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 7.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001731122-26-000668","json":"https://secwatch.observer/filing/0001731122-26-000668.json","markdown":"https://secwatch.observer/filing/0001731122-26-000668.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1553788/000173112226000668/0001731122-26-000668-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1553788/000173112226000668/e7604_8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"February 6, 2026, Lunai Bioworks, Inc. (the “Company”)\nreceived a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)\nnotifying the Company that Nasdaq staff has determined to delist the Company’s securities from The Nasdaq Capital Market. The Notice states that the Company is not in compliance with Nasdaq Listing\nRule 5550(a)(2), which requires a minimum bid price of $1.00 per share, as the bid price of the Company’s securities closed below\n$1.00 per share for 30 consecutive business days from December 23, 2025 through February 5","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112226000221/0001731122-26-000221-index.htm","comparable_excerpt":"April 29, 2026, the Company received notice from NYSE Regulation (the “NYSE”)\nthat the Company is not in compliance with the shareholders’ equity requirement of $6 million as of December 31, 2025 as outlined\nin Section 1","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1553788/000173112226000668/0001731122-26-000668-index.htm"}},{"accession":"0001493152-26-019609","ticker":"VSTD","company_name":"Vestand Inc.","filed_at":"2026-04-29T23:59:59+00:00","headline":"Vestand receives Nasdaq delisting notice for late 10-K filing; may submit compliance plan by May 18, 2026","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 7.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-019609","json":"https://secwatch.observer/filing/0001493152-26-019609.json","markdown":"https://secwatch.observer/filing/0001493152-26-019609.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1898604/000149315226019609/0001493152-26-019609-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1898604/000149315226019609/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"February 6, 2026, Lunai Bioworks, Inc. (the “Company”)\nreceived a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)\nnotifying the Company that Nasdaq staff has determined to delist the Company’s securities from The Nasdaq Capital Market. The Notice states that the Company is not in compliance with Nasdaq Listing\nRule 5550(a)(2), which requires a minimum bid price of $1.00 per share, as the bid price of the Company’s securities closed below\n$1.00 per share for 30 consecutive business days from December 23, 2025 through February 5","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112226000221/0001731122-26-000221-index.htm","comparable_excerpt":"April 23, 2026, Vestand Inc. (the “Company”) received a staff deficiency notice (the “Notice”) from The Nasdaq\nStock Market (“Nasdaq”) indicating that, because Nasdaq has not yet received the Company’s Form 10-K for the","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1898604/000149315226019609/0001493152-26-019609-index.htm"}},{"accession":"0001193125-26-179391","ticker":"JAGX","company_name":"Jaguar Health, Inc.","filed_at":"2026-04-27T23:59:59+00:00","headline":"Jaguar Health granted Nasdaq extension to May 15, 2026; announces 1-for-35 reverse stock split","event_type":"regulatory","sec_items":["3.01","3.03","5.03","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 7.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-179391","json":"https://secwatch.observer/filing/0001193125-26-179391.json","markdown":"https://secwatch.observer/filing/0001193125-26-179391.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526179391/0001193125-26-179391-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526179391/d109088d8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"February 6, 2026, Lunai Bioworks, Inc. (the “Company”)\nreceived a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)\nnotifying the Company that Nasdaq staff has determined to delist the Company’s securities from The Nasdaq Capital Market. The Notice states that the Company is not in compliance with Nasdaq Listing\nRule 5550(a)(2), which requires a minimum bid price of $1.00 per share, as the bid price of the Company’s securities closed below\n$1.00 per share for 30 consecutive business days from December 23, 2025 through February 5","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112226000221/0001731122-26-000221-index.htm","comparable_excerpt":"April 24, 2026, Jaguar Health, Inc. (the “Company”) received a decision letter from the Nasdaq Hearings Panel (“Panel”) granting the Company’s request to continue its listing on The Nasdaq Stock Market LLC (“Nasdaq”), su","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526179391/0001193125-26-179391-index.htm"}},{"accession":"0001213900-26-063575","ticker":"ISPC","company_name":"iSpecimen Inc.","filed_at":"2026-06-01T21:00:15+00:00","headline":"iSpecimen flagged for Nasdaq equity shortfall; equity $814K vs $2.5M minimum","event_type":"regulatory","sec_items":["3.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063575","json":"https://secwatch.observer/filing/0001213900-26-063575.json","markdown":"https://secwatch.observer/filing/0001213900-26-063575.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1558569/000121390026063575/0001213900-26-063575-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1558569/000121390026063575/ea0292875-8k_ispecimen.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"February 6, 2026, Lunai Bioworks, Inc. (the “Company”)\nreceived a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)\nnotifying the Company that Nasdaq staff has determined to delist the Company’s securities from The Nasdaq Capital Market. The Notice states that the Company is not in compliance with Nasdaq Listing\nRule 5550(a)(2), which requires a minimum bid price of $1.00 per share, as the bid price of the Company’s securities closed below\n$1.00 per share for 30 consecutive business days from December 23, 2025 through February 5","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112226000221/0001731122-26-000221-index.htm","comparable_excerpt":"May 29, 2026, iSpecimen Inc. (the “Company”)\nreceived a letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)\nnotifying the Company that it no longer complies with Nasdaq Listing Rule 5550(b)(1) (the “Rule”), which requires a minimum\nof $2,500,000 in stockholders’ equity for continued listing on the Nasdaq Capital Market (the “Capital Market”). As reported in the Company’s Quarterly Report\non Form 10-Q for the period ended March 31, 2026, the Company had stockholders’ equity of $814,038. Nasdaq noted that, as of May\n29, 2026, the Company doe","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1558569/000121390026063575/0001213900-26-063575-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}